Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Outlook Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Outlook Therapeutics Inc
Rating: 0.52266675
Author: Trendlyne DVM scores

about

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

0.50 -0.01 (-1.96%)

New 52W Low today

2.1M

XNAS Volume

XNAS 23 Jan, 2026 4:30 PM (EST)

Not Eligible

Expensive Valuation

5.2 / 100

Technically Bearish

15.7 / 100

1Yr Price target upside is 976%

4 analysts

Outlook Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

New 52W Low today

SWOT Analysis

Outlook Therapeutics Inc Live Price Chart